This study is looking at whether adding a common antifungal medicine called itraconazole can improve treatment for esophageal cancer. Esophageal cancer is becoming more common, and current treatments don't always work well. Previous research suggests that itraconazole might help by blocking certain pathways (Hedgehog, AKT, and angiogenic signaling) that are active in esophageal cancer cells and help them grow. In this study, 78 patients with resectable esophageal or gastroesophageal junction cancer will receive itraconazole along with their usual treatment of chemotherapy, radiation, and surgery. The main goal is to see if itraconazole increases the rate of a "pathological complete response" (meaning no cancer cells are found after treatment). You may be able to join if you are 18 or older, have resectable esophageal or GEJ cancer, and are planning to have standard chemoradiation and surgery.

Study design

This is a Phase II interventional study aiming to enroll 78 participants. It is not specified if it is randomized or blinded.

What's involved

You would take oral itraconazole for two weeks before starting standard chemoradiation, and then for 6-8 weeks after finishing chemoradiation. You would also have standard staging tests and follow-up visits.

Compensation

Not stated in the trial record.

Follow-up

The primary outcome, pathological complete response, is measured at 20 weeks after treatment.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.